ESTRO 35 2016 S383 ________________________________________________________________________________ 1.371 for the 6MV beams, TrueBeam and Versa HD, respectively. The same figure for the 10MV beams were 1.484-1.524, and 1.501-1.543. Concerning beam penetration, TPR20,10 for 6 and 10 flattened and FFF TrueBeam beams were: 0.665, 0.629 (6MV) and 0.738, 0.703 (10MV), while for Versa HD beams are: 0.684, 0.678 (6MV) and 0.734, 0.721 (10MV).
Purpose or Objective: Monte Carlo calculations are increasingly applied as an independent QA tool for pretreatment verification of patient plans for complex treatment delivery techniques such as VMAT. The dose obtained is usually imported to the treatment planning system for further analysis. The analysis can encompass visual comparison of dose distributions as well as qualitative and/or quantitative comparison of Dose Volume Histograms for specific structures. More sophisticated quantitative comparison in 3D includes gamma analysis combining dose difference and distance-to-agreement evaluation generating pass/fail maps. The normalized dose difference (NDD) method is considered to be an extension of the gamma-index concept including locally defined, spatially varying normalization factors. The NDD is reported to be insensitive to the dose grid size. Also, it shows which dose distribution has a higher value at the comparison point (has a sign). The objective of the work is to test the applicability of the NDD method in the Monte Carlo pre-treatment QA procedure, as well as to develop a stand-alone module which will include visual and quantitative analysis.
Material and Methods:
Monte Carlo simulations were performed using the EGSnrc/BEAMnrc code system with modifications, capable to compute dose distributions due to a continuously moving gantry, dynamic multileaf collimator and variable dose rate (I.A. Popescu and J. Lobo, Radiother. Onc.2007) . A Monte Carlo model of a Varian Clinac iX accelerator was used. Patient treatment plans were generated by Eclipse treatment planning system (Varian Medical Systems, USA) and calculated by the AAA algorithm. NDD formalism has been applied in Matlab (Mathworks®) as described in (Jiang SB, et al. Phys Med Biol 2006) .
Results
: Dose distributions for patients in different anatomical regions have been obtained; pelvic and head and neck. Example of NDD analysis for a prostate cancer is shown in the figure.
A 3%, 3 mm tolerance criteria is used. The colour scale varies from ±3%, i.e. the region of acceptance. Negative values indicate that the Eclipse dose (AAA) is lower than the Monte Carlo calculated dose. The Monte Carlo simulations include the air surrounding the patient. Therefore the NDD values outside the patient are negative. All the NDD values are within tolerance on the left transversal slice, i.e. there is agreement between Monte Carlo and AAA. On the right transversal slice, the AAA shows higher target dose in small ventral regions and lower dose at some points in the risk organ (rectum). In general the pass-rate observed is > 95%. A slight dominance of the Monte Carlo dose has been observed in the NDD statistics expressed as a shift of the maximum in the NDD distribution.
Conclusion:
The NDD method can give important information for pre-treatment verification of VMAT plans, which is complementary to the dose analysis in the treatment planning system.
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Material and Methods:
Six patients undergoing passive scatter proton therapy for prostate cancer were enrolled in an IRB approved protocol. The Exradin W1 plastic scintillator was used to measure in vivo skin dose by attaching the detector to the patient's skin at the central axis of each treatment field (2 laterally opposed treatment fields). Measurements were acquired once per week for the entire treatment course resulting in a total of 93 measurements. The detector was first calibrated on a Cobalt-60 unit, and phantom measurements in the proton beam with the W1 and a calibrated parallel plane ion chamber were used to account for the under-response due to ionization quenching. The average dose difference between the Exradin W1 in vivo dose and parallel plane ion chamber in phantom dose over all measurement and per-patient was computed, as well as standard deviations. Furthermore, dose extracted from the treatment planning system was compare to the parallel plane ion chamber. Finally, baseline stability measurements in the cobalt unit were performed weekly for the duration of the study.
Results:
The calibrated detector exhibited a 7% underresponse for 225 MeV proton beams. The temperature underresponse was 4% when used at 37° C (relative to the response at the calibration temperature of 20° C). The detector exhibited a stable response and was within 1% for the duration of the study (144 days). The average dose difference between the Exradin W1 and parallel plane ion chamber over all patient measurements was 0.27 ± 0.67% after applying the temperature and quenching correction factors. The dose difference between the Exradin W1 in vivo measurements and parallel plane ion chamber for all six patients treatment fields throughout the study were all within ± 2% with a standard deviation of 0.67% (see figure 1) . Figure 1 Dose difference between Exradin W1 in vivo dose and parallel plane ion chamber dose for every patient during the study.
